Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.55 |
| ▸ | CDK9 | P50750 | 2/20 | 0.55 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.55 |
| ▸ | CDK14 | O94921 | 13/20 | 0.55 |
| ▸ | CCNY | Q8ND76 | 12/20 | 0.55 |
| ▸ | CDK2 | P24941 | 6/20 | 0.55 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.55 |
| ▸ | CDK4 | P11802 | 2/20 | 0.55 |
| ▸ | CDK1 | P06493 | 2/20 | 0.55 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.55 |
| ▸ | CASK | O14936 | 1/20 | 0.55 |
| ▸ | CDKL5 | O76039 | 1/20 | 0.55 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.55 |
| ▸ | MAK | P20794 | 1/20 | 0.55 |
| ▸ | CDK11B | P21127 | 1/20 | 0.55 |
| ▸ | CCND1 | P24385 | 1/20 | 0.55 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.55 |
| ▸ | CCND3 | P30281 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22594270 | 0.87 | CDK14 (0.59) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL22022383 | 0.87 | CDK5 (0.59) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL29108698 | 0.85 | CDK5 (0.55) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL25992121 | 0.84 | CDK5 (0.54) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL29243302 | 0.84 | CDK5 (0.54) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL22582171 | 0.84 | CDK5 (0.54) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL30915456 | 0.83 | CDK5 (0.57) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL22594259 | 0.83 | CDK5 (0.52) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL22594266 | 0.82 | CDK14 (0.52) | CDK5CCNT1CDK9CDK5R1CDK14 | |
| SCHEMBL30915451 | 0.82 | CDK5 (0.60) | CDK5CCNT1CDK9CDK5R1CDK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2022-06-30 | — | — | US | disclosed |
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-01-18 | — | — | US | disclosed |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | SHANGHAI JUNSHI BIOSCIENCES CO., LTD. (CN) | 2020-10-29 | — | — | US | disclosed |
| WO-2020215156-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2020-10-29 | — | — | WO | disclosed |
| US-8013163-B2 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2011-09-06 | — | — | US | disclosed |
| EP-2046327-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2046330-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-15 | — | — | EP | disclosed |
| EP-2043635-A2 | PHARMACEUTICAL COMBINATIONS | Astex Therapeutics Limited (GB) | 2009-04-08 | — | — | EP | disclosed |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | ASTEX THERAPEUTICS LIMITED (UK) | 2009-01-08 | — | — | US | disclosed |
| WO-2008009954-A1 | MEDICAL USE OF CYCLIN DEPENDENT KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008007122-A2 | COMBINATIONS OF PYRAZOLE DERIVATIVES FOR THE INHIBITION OF CDKS AND GSK'S | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| WO-2008001101-A2 | PHARMACEUTICAL COMBINATIONS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11225497-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK5 26/4885CCNT1 36/4885CDK9 7/4885 |
| US-20220204541-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CDK5 26/4885CCNT1 36/4885CDK9 7/4885 |
| US-11725020-B2 | Prodrugs of a CDK inhibitor for treating cancers | CDK3, CDK1, GSK3B | CDK5 26/4885CCNT1 36/4885CDK9 7/4885 |
| US-20090012124-A1 | 4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors | MAP4K2, MAPKAPK2, MAP4K1 | CDK5 49/4885CCNT1 2901/4885CDK9 150/4885 |
| US-20200339615-A1 | PRODRUGS OF A CDK INHIBITOR FOR TREATING CANCERS | CDK3, CDK1, GSK3B | CDK5 26/4885CCNT1 36/4885CDK9 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.